SI2020996T1 - Postopek in sestavki za zdravljenje hematološkihmalignosti - Google Patents

Postopek in sestavki za zdravljenje hematološkihmalignosti

Info

Publication number
SI2020996T1
SI2020996T1 SI200730862T SI200730862T SI2020996T1 SI 2020996 T1 SI2020996 T1 SI 2020996T1 SI 200730862 T SI200730862 T SI 200730862T SI 200730862 T SI200730862 T SI 200730862T SI 2020996 T1 SI2020996 T1 SI 2020996T1
Authority
SI
Slovenia
Prior art keywords
hematological malignancies
compositions
treating hematological
compound
salt
Prior art date
Application number
SI200730862T
Other languages
English (en)
Inventor
Lee S Chong
William A Lee
Adrian S Ray
Hans C Reiser
Daniel B Tumas
William J Watkins
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of SI2020996T1 publication Critical patent/SI2020996T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processing Of Solid Wastes (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200730862T 2006-05-16 2007-05-16 Postopek in sestavki za zdravljenje hematološkihmalignosti SI2020996T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80098306P 2006-05-16 2006-05-16
US83180506P 2006-07-18 2006-07-18

Publications (1)

Publication Number Publication Date
SI2020996T1 true SI2020996T1 (sl) 2012-03-30

Family

ID=38578698

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200730862T SI2020996T1 (sl) 2006-05-16 2007-05-16 Postopek in sestavki za zdravljenje hematološkihmalignosti

Country Status (20)

Country Link
US (3) US20090258840A1 (sl)
EP (1) EP2020996B1 (sl)
JP (2) JP5544165B2 (sl)
KR (1) KR101424832B1 (sl)
CN (1) CN101442994B (sl)
AT (1) ATE534377T1 (sl)
AU (1) AU2007254309B2 (sl)
BR (1) BRPI0711646C1 (sl)
CA (1) CA2652048C (sl)
CY (1) CY1112377T1 (sl)
DK (1) DK2020996T3 (sl)
EA (1) EA016995B1 (sl)
ES (1) ES2377467T3 (sl)
HK (1) HK1127913A1 (sl)
MX (1) MX2008014665A (sl)
NZ (1) NZ572368A (sl)
PL (1) PL2020996T3 (sl)
PT (1) PT2020996E (sl)
SI (1) SI2020996T1 (sl)
WO (1) WO2007136650A2 (sl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
JP5323684B2 (ja) 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
WO2007136650A2 (en) * 2006-05-16 2007-11-29 Gilead Sciences, Inc. Method and compositions for treating hematological malignancies
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
PL2731947T3 (pl) 2011-07-15 2019-07-31 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
CN111989335B (zh) * 2018-06-12 2023-06-13 四川科伦博泰生物医药股份有限公司 膦酰胺酯化合物及其盐和相关晶体形式、制备方法和用途
CN112168829B (zh) * 2020-09-24 2022-02-15 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
NZ535408A (en) 2000-07-21 2006-09-29 Gilead Sciences Inc Method for selecting prodrugs of phosphonate nucleotide analogues
EP1864967A1 (en) * 2001-02-12 2007-12-12 Wyeth Method for preparing O-desmethyl-venlafaxine
ES2258652T3 (es) * 2001-11-29 2006-09-01 Pfizer Products Inc. Sales de succinato de 5,8,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de los mismos.
RS46404A (en) * 2001-12-12 2006-10-27 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-(4-(3-methyul-pyridin-3- yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide,its preparation and its use against cancer
WO2004037161A2 (en) * 2002-05-13 2004-05-06 Metabasis Therapeutics, Inc. Cyclic prodrugs of pmea one of its analogues
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
EP1658276B1 (en) * 2003-08-18 2012-10-10 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
DK1716162T3 (da) * 2003-12-30 2011-01-10 Gilead Sciences Inc Phosphonater, amidomonophosphonater, amidobisphosphonater til behandling af virussygdomme
EP1732569B1 (en) 2004-01-21 2009-10-14 Gilead Sciences, Inc. Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
CA2632540A1 (en) * 2005-12-16 2007-07-05 Wyeth Lyophilized compositions of a triazolopyrimidine compound
WO2007136650A2 (en) * 2006-05-16 2007-11-29 Gilead Sciences, Inc. Method and compositions for treating hematological malignancies

Also Published As

Publication number Publication date
BRPI0711646A2 (pt) 2011-11-29
US20090258840A1 (en) 2009-10-15
DK2020996T3 (da) 2012-02-27
US20080039427A1 (en) 2008-02-14
NZ572368A (en) 2011-04-29
CN101442994B (zh) 2013-03-06
BRPI0711646C1 (pt) 2021-05-25
WO2007136650A2 (en) 2007-11-29
CA2652048A1 (en) 2007-11-29
EP2020996B1 (en) 2011-11-23
HK1127913A1 (en) 2009-10-09
CA2652048C (en) 2012-12-11
ES2377467T3 (es) 2012-03-27
PT2020996E (pt) 2012-02-20
BRPI0711646B1 (pt) 2020-12-01
AU2007254309B2 (en) 2012-05-03
ATE534377T1 (de) 2011-12-15
PL2020996T3 (pl) 2012-04-30
BRPI0711646B8 (pt) 2021-04-06
KR20090015122A (ko) 2009-02-11
JP2013100324A (ja) 2013-05-23
JP2009537539A (ja) 2009-10-29
EP2020996A2 (en) 2009-02-11
US8435969B2 (en) 2013-05-07
AU2007254309A1 (en) 2007-11-29
US20110172192A1 (en) 2011-07-14
EA200802333A1 (ru) 2009-04-28
MX2008014665A (es) 2008-11-28
WO2007136650A3 (en) 2008-01-24
CN101442994A (zh) 2009-05-27
JP5544165B2 (ja) 2014-07-09
EA016995B1 (ru) 2012-09-28
CY1112377T1 (el) 2015-12-09
KR101424832B1 (ko) 2014-08-06

Similar Documents

Publication Publication Date Title
HK1127913A1 (en) Method and compositions for treating hematological malignancies
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
SG179418A1 (en) Inhibitors of the hedgehog pathway
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
JO2848B1 (en) Organic compounds
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
UA96777C2 (ru) Фенилпропионамидные соединения и их применение как опиоидных агонистов
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
HK1093159A1 (en) Monocyclic heterocycles as kinase inhibitors
MX2009005934A (es) Compuestos organicos.
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
MX2011007165A (es) Derivados de piridazinona.
BRPI0821114A2 (pt) Composto, uso de um composto e método para tratar qualquer mamífero afetado por câncer
MX2009003102A (es) INDOLILALQUILPIRIDIN-2-AMINAS PARA LA INHIBICION DE ß-SECRETASA.
MX2011007232A (es) Derivados de benzotiazolona.
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors
TW200732314A (en) Substituted thiazoles and their use
MX2011007209A (es) Derivados de piridazinona.
UA97540C2 (ru) Замещенные хиноксалином пиперидиновые соединения и их применение